Updates

February 25, 2021August 24, 2022
Cancer-sniffing Dogs May Help Train Robot Noses to Detect Tumors Early

Understanding the molecular components of odors used by trained dogs to detect prostate cancer could help researchers to develop computers with similar diagnostic accuracy, a ... Read more
February 23, 2021February 23, 2021
Prolaris Test Helps ID Higher-risk Patients Who May Safely Skip ADT

Prolaris — a genetic test that predicts the aggressiveness of prostate cancer — can accurately identify which men with intermediate- or high-risk disease will benefit from ... Read more
February 18, 2021February 18, 2021
Erleada-Zytiga Combo Delays Progression in mCRPC Patients, Phase 3 Trial Reports

Combining Erleada (apalutamide) and Zytiga (abiraterone acetate) to treat metastatic castration-resistant prostate cancer (mCRPC) significantly extends the time patients live without signs of disease worsening, compared ... Read more
February 16, 2021February 16, 2021
Erleada-ADT Combo Found to Prolong Survival, Delay Cancer Worsening

When given in combination with androgen deprivation therapy or ADT, Erleada (apalutamide) significantly prolonged the lives of men with metastatic hormone-sensitive prostate cancer (mHSPC) — ... Read more
February 11, 2021February 11, 2021
‘TRUE Love’ Contest Calls for Entries Honoring Caregivers

With help from actress Kristen Bell, the Prostate Cancer Foundation (PCF) has opened its 4th annual TRUE Love contest for entries that pay tribute to ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

September 12, 2017September 12, 2017

Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds

News

Two treatment approaches — Zytiga (abiraterone acetate) plus prednisolone (AAP) or Taxotere (docetaxel) — provided patients with high-risk prostate cancer similar benefits when added to standard hormone deprivation therapy, according to data recently presented at the European Society for Medical ... Read more

Cancer-sniffing Dogs May Help Train Robot Noses to Detect Tumors Early

Prolaris Test Helps ID Higher-risk Patients Who May Safely Skip ADT

Erleada-Zytiga Combo Delays Progression in mCRPC Patients, Phase 3 Trial Reports

Erleada-ADT Combo Found to Prolong Survival, Delay Cancer Worsening

‘TRUE Love’ Contest Calls for Entries Honoring Caregivers

New AI Tool May Better Predict Relapse After Surgery

Dosing Begins in Phase 1 Trial of FT-7051 for Advanced, Resistant Cancer

NBA Teams Join Efforts to Raise Money and Awareness

Biological Clock Protein CRY-1 Eyed as Therapeutic Target

EPI-7386 Combo Therapies Enter Trial for Certain mCRPC Patients

Daily Coffee Drinking Lowers Prostate Cancer Risk, Study Suggests

Subscribe to our mailing list

Active Surveillance Safe for Black Men With Low-risk Diagnosis, Study Finds

Nubeqa Prescribing Information Updated With New Survival Data

Orgovyx Now Available in US for Advanced Prostate Cancer

Oral ARV-110 Shows Promise in Heavily Treated mCRPC Patients

Long-term ADT Found to Raise Risk of Cardiovascular Death

FDA Approves Orgovyx, Oral ADT for Advanced Prostate Cancer

Teams Working in Advanced Cancer Win 2020 PCF Challenge Awards

Study Describes New Way to Place CRISPR/Cas9 Into Cancer Cells

Canada Approves Lynparza for Metastatic CRPC Patients With Certain Gene Mutations

FDA Puts RV001 on Fast Track for Treating Prostate Cancer

FDA Approves First PSMA-targeted PET Imaging Agent for Prostate Cancer

FDA Approves FoundationOne Liquid CDx as Companion Test for Lynparza in mCRPC Patients

New $100M Program Aims to Improve Diversity in Clinical Trials

PCF Helps Fund 2 Centers of Excellence to Treat Veterans With Prostate Cancer

Puerto Rico to Test miR’s ‘Liquid Biopsy’ in Detecting Prostate Cancers

AI-enabled Software To Detect Prostate Cancer Bone Metastases Clears FDA

UK Study to Assess Causes of Greater Prostate Cancer Risk Among Black Men

European Commission OKs Lynparza for Metastatic CRPC With BRCA Mutations

Hold Lifted on Phase 1 Trial Testing P-PSMA-101 CAR T-cell Therapy in mCRPC

CAR T-Cell Therapy, MB-105, Shows Promise in Metastatic CRPC Patient in Phase 1 Trial

FDA Clears Ezra Prostate AI, a First for Cancer Imaging

New Targeted Therapy Trial Opens, Part of PC-BETS Metastatic CRPC Study

ADT Not Needed With Radiation in Favorable Intermediate-Risk PC

Provenge Improves Survival in mCRPC Patients Over Xtandi, Zytiga, Real-world Study Finds

Trial to Test Focal Laser Ablation Therapy for Localized Prostate Cancer

New AI Algorithm Can Accurately Identify, Grade Prostate Cancer

Veru Completes Enrollment for Second Part of Phase 1/2 VERU-111 Trial

Lantheus Seeks FDA Approval of PyL Prostate Cancer Imaging Agent

Relugolix Fails to Delay Castration Resistance in Advanced PC, Trial Shows

Most nmCRPC Patients Can Safely Take Full Dose of Nubeqa, Trial Analysis Shows

Phase 1 Trial of Oral Treatment for Metastatic CRPC Doses First Patient